When was Pelican Therapeutics founded?

Pelican Therapeutics was founded in 2011 and raised its 1st funding round 3 years after it was founded.

Where is Pelican Therapeutics located?

Pelican Therapeutics is headquartered in Austin, United States.

How many employees does Pelican Therapeutics have?

As of Jul 01, 2024, the latest employee count at Pelican Therapeutics is 4.

Is Pelican Therapeutics a funded company?

Pelican Therapeutics is a funded company, having raised a total of $410K across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 06, 2014.

When was the latest funding round of Pelican Therapeutics?

Pelican Therapeutics' latest funding was a $***** Grant (prize money) round on Jan 07, 2020, with participation from 1 investor. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $957M in funding in 2026 to date.

Where does Pelican Therapeutics rank among its competitors?

Pelican Therapeutics ranks 2750th amongst 3264 active competitors, of which 1126 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Pelican Therapeutics?

Pelican Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

Pelican Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Pelican Therapeutics is developing biologic agents that represent the next generation of Tumor Necrosis Factor (TNF) based immunotherapy. Its lead product candidate is a humanized monoclonal antibody that is a functional agonist of human TNFRSF25. This antibody provides highly selective and potent stimulation of ‘memory’ CD8+ cytotoxic T cells. Its second product candidate is a human TL1A-Ig fusion protein that can be used to cause proliferation of regulatory T cells in patients.

Website: pelicantherapeutics.com
Email ID: *****@pelicantherapeutics.com

Key Metrics

Founded Year

2011

Location

Austin, United States

Stage

Acqui-Hired

Total Funding

$410K in 4 rounds

Latest Funding Round

Grant (prize money), Jan 07, 2020, $*****

Investors

HHS

Ranked

2750^th among 3264 active competitors

Employee Count

4 as on Jul 01, 2024

Similar Companies

Jazz Pharmaceuticals & 3036 more

View Pelican Therapeutics' full profile

Pelican Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Pelican Therapeutics, Inc. CIN: 272038564 , United States, Active	Dec 31, 2010	-	-	-

Pelican Therapeutics has raised a total funding of $410K over 4 rounds. Its first funding round was on Jun 06, 2014. Its latest funding round was a Grant (prize money) round on Jan 07, 2020 for $*****. 1 investor participated in its latest round. Pelican Therapeutics has 1 institutional investor.

Here is the list of recent funding rounds of Pelican Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 07, 2020	8696462	Grant (prize money)	8395916	4518283	3729545	5021931
May 19, 2016	4369708	Grant (prize money)	8348592	4513052	9654540	6564336
Aug 18, 2015	7820749	Seed	2079836	5557222	3511111	5065725

Access funding benchmarks and valuations. Sign up today!

View details of Pelican Therapeutics's funding rounds and investors

The founders of Pelican Therapeutics is Taylor Schreiber D.

Here are the details of Pelican Therapeutics' key team members:

Taylor Schreiber D: Co-Founder and Scientific Advisor of Pelican Therapeutics.

View details of Pelican Therapeutics's Founder profiles and Board Members

Pelican Therapeutics' employee count trend

Pelican Therapeutics has 4 employees as of Jul 24. Here is Pelican Therapeutics's employee count trend over the years:

Employee count trend for Pelican Therapeutics

Uncover Pelican Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Pelican Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Pelican Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 31 others	71/100
2750th	Pelican Therapeutics 2011, Austin (United States), Acqui-Hired	Developing antibody to stimulate memory CD8+ cytotoxic T cells for the treatment of cancer.	$410K	HHS	23/100